What can help before joint surgery?

What can help at home first?

Do less of the motion that caused the flare while keeping gentle movement. Several short sessions may feel better than one hard workout. Strength work supports the muscles that steady the sore joint. Stop when the joint becomes much more swollen.

A cane can reduce the load on a sore leg. A brace may steady some knees during a walk. Cold often helps after a new flare, while heat can loosen stiffness. Medicine isn't safe for everyone, so ask a doctor first.

When does an office visit help?

An office visit helps when your ache keeps returning. The doctor or nurse tests movement and strength, then checks swelling and tender places. Your report about the timing also matters, and an X-ray can show arthritis or an old injury.

The discussion may cover physical therapy, medicine, a joint shot, or surgery. Each choice brings different costs, recovery needs, and limits. Ask for the exam result before you decide. First identify why the joint hurts, then choose the care.

What can come before surgery?

Regenerative treatments are nonsurgical joint shots prepared from blood, marrow, fat, or donated tissue. PRP, a shot made from concentrated platelets in your own blood, has mixed but broader research. Research for marrow and fat shots is thinner. No one result covers every source or every joint.

Joint preservation means trying to keep useful movement and delay major surgery when reasonable. Any choice should aim to improve quality of life, including walking and sleeping. It shouldn't keep surgery out of the discussion. Severe damage or little useful movement deserves a surgeon's review now.

Sources

1. The OARSI non-surgical management guideline evaluated 60 interventions with GRADE methodology and built its recommendations around core treatments - structured exercise, weight management and self-management education - for every patient with knee osteoarthritis, regardless of what else is added.

   Bannuru RR, et al. — OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage, 2019. DOI: 10.1016/j.joca.2019.06.011.

2. In a 480-patient, four-arm, multicenter randomized phase 2/3 trial, none of three orthobiologic cell injections - autologous bone marrow aspirate concentrate, autologous adipose stromal vascular fraction, or allogeneic umbilical cord tissue-derived mesenchymal stromal cells - was superior to any other, or to a corticosteroid injection control, on pain at 12 months.

   Mautner K, et al. — Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial. Nat Med, 2023. DOI: 10.1038/s41591-023-02632-w.

3. A 2025 systematic review and meta-analysis of 8 randomized trials in 502 patients found intra-articular mesenchymal stem cells improved WOMAC scores versus control at 6 months (MD 7.44, 95% CI 1.45-13.42) and 12 months (MD 10.31, 95% CI 0.96-19.67), with wide confidence intervals and a small pooled sample.

   Cao M, et al. — Efficacy and safety of mesenchymal stem cells in knee osteoarthritis: a systematic review and meta-analysis of randomized controlled trials. Stem Cell Res Ther, 2025. DOI: 10.1186/s13287-025-04252-2.

4. A 2025 systematic review and meta-analysis of 6 randomized trials found microfragmented adipose tissue and PRP both reached the minimal clinically important difference on most outcomes to 12 months, with no clear superiority of the fat-derived preparation despite its higher price.

   Park YB, et al. — Microfragmented Adipose Tissue as an Alternative to Platelet-Rich Plasma for Intra-articular Injection in Knee Osteoarthritis: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Am J Sports Med, 2025. DOI: 10.1177/03635465251337759.

5. A randomized trial comparing commercially available systems in 71 patients found microfragmented adipose tissue equivalent to leukocyte-rich PRP on KOOS pain at 12 months.

   Baria M, et al. — Microfragmented Adipose Tissue Is Equivalent to Platelet-Rich Plasma for Knee Osteoarthritis at 12 Months Posttreatment: A Randomized Controlled Trial. Orthop J Sports Med, 2024. DOI: 10.1177/23259671241233916.

6. A 2025 randomized trial of 66 knee osteoarthritis patients compared a single adipose stromal vascular fraction injection, conventional rehabilitation alone, and the two combined over 12 months - a design that treats exercise-based rehabilitation as a genuine comparator rather than an afterthought.

   Lu J, et al. — Intraarticular injection of the stromal vascular fraction for the treatment of knee osteoarthritis a prospective randomized controlled clinical trial. Sci Rep, 2025. DOI: 10.1038/s41598-025-09398-w.

7. A 2024 systematic review of bone marrow aspirate concentrate for HIP osteoarthritis found the clinical evidence base thinner than for the knee, with most studies uncontrolled - the joint matters, and evidence does not transfer across joints.

   Chandrashekar S, et al. — Safety and Efficacy of Bone-Marrow Aspirate Concentrate in Hip Osteoarthritis: A Systematic Review of Current Clinical Evidence. Indian J Orthop, 2024. DOI: 10.1007/s43465-024-01183-7.

8. A 2025 meta-analysis of 73 double-blind placebo-controlled injection trials in 5,895 knee osteoarthritis patients found placebo responder rates above 50 percent at 1, 3 and 6 months, declining by 12 months - which is why any uncontrolled 'our patients improved' claim from a clinic is uninterpretable.

   Previtali D, et al. — Placebo response to intra-articular injections in knee osteoarthritis: magnitude, evolution over time, and influencing factors. A systematic review and meta-analysis with meta-regression. EFORT Open Rev, 2025. DOI: 10.1530/EOR-2025-0022.

9. FDA states in its consumer alert that the only FDA-approved stem cell products in the United States are blood-forming stem cells derived from umbilical cord blood, approved for disorders of the blood-forming system, and that NONE of these products - stem cells, stromal vascular fraction, umbilical cord blood, Wharton's jelly or amniotic fluid - has been approved for the treatment of any orthopedic condition, including osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain or shoulder pain.

   US Food and Drug Administration, Center for Biologics Evaluation and Research — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. , 2020.